Equillium, Inc. EQ
1.46 USD -0.04 (-3.00%)
At closeNov 10, 2026, 4:00 PM EST
1.50 +0.04 +3.09%
After hours · Nov 10, 4:00 PM ET
1.45 Day range 1.53
0.84 52-week range 3.20
- YTD
- -6.13%
- 1 year
- +50.00%
News
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session Gainers Revolution Medicines (NASDAQ:RVMD) stock rose 14.1% to $227.83 during Wednesday's after-market session. The market value of their outstanding shares is at $41.6 billion. As per the news, the…
benzinga.com Equillium Doses First Patient In Australia In Its Phase 1 Clinical Study Of EQ504 To Treat Serious Inflammatory Diseases Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that the first subject has been dosed in…
globenewswire.com Equillium Announces First Subject Dosed in Phase 1 Clinical Trial of EQ504 Topline Phase 1 proof-of-mechanism data anticipated in Q2 2027 Randomized, double-blind, placebo-controlled study will evaluate safety, tolerability, PK and PD of EQ504 Triggers Milestone Closing of…
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session Gainers SciSparc (NASDAQ:SPRC) shares moved upwards by 39.4% to $1.52 during Monday's pre-market session. Xencor (NASDAQ:XNCR) stock moved upwards by 29.46% to $32.6. The company's market cap stands…
benzinga.com Leerink Partners Assumes Equillium at Outperform, Announces Price Target of $6 Leerink Partners analyst Will Soghikian assumes Equillium (NASDAQ:EQ) with a Outperform rating and announces Price Target of $6.
globenewswire.com Equillium Announces Poster Presentation at the 50th Anniversary La Jolla Immunology Conference New preclinical data further characterizes EQ504's coordinated effects across epithelial and immune compartments in intestinal inflammation New preclinical data further characterizes EQ504's…
globenewswire.com Equillium Receives Australian Regulatory Clearance to Initiate First-in-Human Clinical Trial of EQ504 On track to initiate dosing by early November 2026; topline Phase 1 proof-of-mechanism data anticipated approximately six months following study initiation
globenewswire.com Equillium Announces Poster Presentations at the 7th International AHR Conference New preclinical data further characterize EQ504's effects on epithelial barrier repair and immune regulation New preclinical data further characterize EQ504's effects on epithelial barrier repair and…
defenseworld.net Equillium Eyes Q4 Phase I Start for Ulcerative Colitis Drug EQ504 Equillium (NASDAQ: EQ) Chief Scientific Officer Stephen Connelly outlined the company's plans to advance its lead programs, including an oral aryl hydrocarbon receptor, or AhR, modulator for…
marketbeat.com Equillium Eyes Q4 Phase I Start for Ulcerative Colitis Drug EQ504 Equillium NASDAQ: EQ Chief Scientific Officer Stephen Connelly outlined the company's plans to advance its lead programs, including an oral aryl hydrocarbon receptor, or AhR, modulator for ulcerative…
globenewswire.com Equillium to Participate in Stifel's 2026 Virtual Immunology and Inflammation Forum LA JOLLA, Calif., Sept. 16, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today…
reuters.com EQ Resources to take 10% stake in Nevada tungsten project JV with Elmet, Blue Moon Australian miner EQ Resources said on Tuesday it would take a 10% stake in a joint venture with Nasdaq-listed Elmet Group and Blue Moon Metals to restart the Springer tungsten project in Nevada.
globenewswire.com Equillium to Participate in Upcoming Investor Conferences LA JOLLA, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today…
globenewswire.com Equillium Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights Phase 1 proof-of-mechanism study of EQ504 initiation expected in Q4 2026, with data expected approximately six months thereafter Cash and cash equivalents of $57.2 million expected to fund operations…
defenseworld.net Equillium, Inc. (NASDAQ:EQ) Given Consensus Recommendation of “Moderate Buy” by Analysts Shares of Equillium, Inc. (NASDAQ: EQ - Get Free Report) have received a consensus rating of "Moderate Buy" from the eleven research firms that are currently covering the firm, Marketbeat reports.…
benzinga.com Piper Sandler Initiates Coverage On Equillium with Overweight Rating, Announces Price Target of $20 Piper Sandler analyst Yasmeen Rahimi initiates coverage on Equillium (NASDAQ:EQ) with a Overweight rating and announces Price Target of $20.
accessnewswire.com EQ Works Expands Multi-Year Partnership with Leading Canadian Publisher to Include SaaS License for ClearLake Three-year renewal follows early campaign results that delivered up to 40% increases in average order value and nearly double the conversion rates using ClearLake TORONTO, ON / ACCESS Newswire / June…
globenewswire.com Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) LA JOLLA, Calif., June 02, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today…
seekingalpha.com Equillium, Inc. (EQ) Discusses Mechanistic Insights Linking AhR Signaling and miR-124 in Inflammatory Disease Transcript Equillium, Inc. (EQ) Discusses Mechanistic Insights Linking AhR Signaling and miR-124 in Inflammatory Disease Transcript
marketbeat.com Equillium Links AhR Activation to miR-124 as EQ504 Heads Toward Phase 1 Equillium NASDAQ: EQ Chief Scientific Officer Stephen Connelly outlined new preclinical data during a company webinar focused on the relationship between the aryl hydrocarbon receptor, or AhR, and…
globenewswire.com Equillium to Participate in the 2026 Jefferies Global Healthcare Conference LA JOLLA, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today…- benzinga.com Leerink Partners Upgrades Equillium to Outperform, Raises Price Target to $6 Leerink Partners analyst Thomas Smith upgrades Equillium (NASDAQ:EQ) from Market Perform to Outperform and raises the price target from $1 to $6.
globenewswire.com Equillium to Host Virtual Investor Event to Share New Insights into the Aryl Hydrocarbon Receptor (AhR) and miR-124 Axis LA JOLLA, Calif., May 20, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today…- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
benzinga.com Equillium Q1 EPS $(0.06) Misses $(0.05) Estimate Equillium (NASDAQ:EQ) reported quarterly losses of $(0.06) per share which missed the analyst consensus estimate of $(0.05) by 20 percent. This is a 75 percent increase over losses of $(0.24) per…
globenewswire.com Equillium Reports First Quarter 2026 Financial Results and Corporate Highlights Phase 1 proof-of-mechanism study of EQ504 on track to initiate in mid-2026, with data expected approximately six months thereafter
globenewswire.com Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) LA JOLLA, Calif., May 01, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today…
globenewswire.com Equiniti (EQ) Launches DealTrax™: A Digital-First Platform for Corporate Actions and M&A Events DealTrax Highlights Include: Powerful Tools & Streamlined Processes: Quick, efficient deal setup with digital capabilities Speed: Faster payment delivery to holders Seamless Delivery: Full-service…
benzinga.com B. Riley Securities Initiates Coverage On Equillium with Buy Rating, Announces Price Target of $6 B. Riley Securities analyst William Woods initiates coverage on Equillium (NASDAQ:EQ) with a Buy rating and announces Price Target of $6.
benzinga.com Raymond James Initiates Coverage On Equillium with Strong Buy Rating, Announces Price Target of $6 Raymond James analyst Martin Auster initiates coverage on Equillium (NASDAQ:EQ) with a Strong Buy rating and announces Price Target of $6.
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session - benzinga.com Cantor Fitzgerald Initiates Coverage On Equillium with Overweight Rating, Announces Price Target of $10 Cantor Fitzgerald analyst Emma Nealon initiates coverage on Equillium (NASDAQ:EQ) with a Overweight rating and announces Price Target of $10.
- benzinga.com Equillium Q4 EPS $(0.04) Beats $(0.14) Estimate Equillium (NASDAQ:EQ) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.14) by 70.37 percent. This is a 75 percent increase over losses of $(0.16) per…
- benzinga.com Roth Capital Initiates Coverage On Equillium with Buy Rating, Announces Price Target of $12 Roth Capital analyst Adam Walsh initiates coverage on Equillium (NASDAQ:EQ) with a Buy rating and announces Price Target of $12.
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session - benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session - benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session 
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session 
benzinga.com Why Is Equillium Stock Soaring Monday? Equillium stock is trading higher Monday after the company announced up to $50 million in financing through a securities purchase agreement with investors to advance EQ504.
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session 
benzinga.com Gold Down Over 2%; Monday.com Shares Tumble After Q2 Results 
benzinga.com US Stocks Mixed; Owens & Minor Posts Downbeat Earnings - benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session